2[2]Thai HM,V an HT,Gaballa MA,et al.Effects of A T1 receptor blockade after myocardial infract on myocardial fibrosis,stiffness,and contractility.AM J Physical,2005,276 (8):873-880.
二级参考文献12
1Sweherg K, Pfeffer W,Granger C,et al. Candersartan in heart failure assessment of reduction in mortality and morbidity (CHARM):Rationale and design[J]. J Card Fail, 1999, 5(1):276.
2Suzuki M,Hamada M,Yamamoto K,et al. Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events[J]. Hypertens Res, 2002, 25(5):669.
3Sudoh T,Kangawa K,Minamion N,et al.A new natriuretic peptide in porcine brain[J].Nature,1988,332(1):78.
4Gheorghiade M, Bonow R O. Chronic heart failure in the United States: a manifestation of coronary artery disease[J]. Circulation, 1988,97(2):282.
5McDonagh T A, Robb S D, Murdoch D R, et al. Biochemical detection of left-ventricular systolic dysfunction[J]. Lancet,1998,351:9.
6de Lemos J A, Mcguire D F, Drazner M H. B-type natriuretic peptide in cardiovascular disease[J]. Lancet, 2003,362(2):316.
7Maisel A S, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure[J]. N Engl J Med, 2002, 347(3):161.
8Maisel A. B-type nariurtic peptide levels:a potential novel white count for congestive heart failure[J]. J Card Fail,2001,7(2):183.
9Selvais P L.Donckier J E,Robert A,et al.Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure:influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation[J].Eur J Clin Invest,1998,28(7):636.
10Yoshimura M,Yasue H,Ogawa H.Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure[J].Can J Physiol Pharmacol,2001,79(8):730.
1Devereux RB,Alonso DR,Lutas EM,et al.Echocardiographic assessment of left ventricular hypertrophy:comparison to necropsy findings[J].Am J Cardiol,1986,57:450-458.
